BALTIMORE - The American subsidiary of Indian drug maker Ranbaxy Laboratories Ltd. on May 13 agreed to pay $500 million in criminal fines and civil penalties and to plead guilty to seven counts of making adulterated prescription drugs, filing false statements about drug quality and causing false claims to be filed with federal health care programs (United States of America v. Ranbaxy USA, Inc., 13-cr-238 and United States ex rel. Dinesh S. Thakur v. Ranbaxy Laboratories Limited, No. 07-962, D. Md.).